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Neuroprotective Drug for Nerve 
Trauma Revealed Using Artificial 
Intelligence
David Romeo-Guitart  1, Joaquim Forés2, Mireia Herrando-Grabulosa1, Raquel Valls3,  
Tatiana Leiva-Rodríguez  1, Elena Galea4,7, Francisco González-Pérez1, Xavier Navarro  1, 
Valerie Petegnief5, Assumpció Bosch6, Mireia Coma3, José Manuel Mas3 & Caty Casas  1
Here we used a systems biology approach and artificial intelligence to identify a neuroprotective 
agent for the treatment of peripheral nerve root avulsion. Based on accumulated knowledge of the 
neurodegenerative and neuroprotective processes that occur in motoneurons after root avulsion, 
we built up protein networks and converted them into mathematical models. Unbiased proteomic 
data from our preclinical models were used for machine learning algorithms and for restrictions to 
be imposed on mathematical solutions. Solutions allowed us to identify combinations of repurposed 
drugs as potential neuroprotective agents and we validated them in our preclinical models. The best 
one, NeuroHeal, neuroprotected motoneurons, exerted anti-inflammatory properties and promoted 
functional locomotor recovery. NeuroHeal endorsed the activation of Sirtuin 1, which was essential 
for its neuroprotective effect. These results support the value of network-centric approaches for drug 
discovery and demonstrate the efficacy of NeuroHeal as adjuvant treatment with surgical repair for 
nervous system trauma.
Common diseases of the central nervous system (CNS), including psychiatric disorders and neurodegeneration, 
are caused by multiple molecular abnormalities as opposed to individual defects. Likewise, recovery from CNS 
trauma requires multiple strategies encompassing neuroprotection and repair and regeneration of CNS cells. It 
follows that effective therapies must target multiple pathways rather than single proteins. Systems biology is an 
indispensable analytical tool in drug discovery for complex diseases. First, it allows for a necessary shift from a 
gene-centric to a network-centric view that takes protein targets back to their physiological context, such that a 
systemic perspective of the environment is gained without losing molecular details. Second, it facilitates the gen-
eration of multi-component therapies by repurposing existing drugs with well-established safety, bioavailability, 
and pharmacology profiles.
Here we report the discovery of a neuroprotective and pro-regenerative drug combination with the therapeu-
tic performance mapping system (TPMS), a platform for drug discovery based on systems biology and artificial 
intelligence (www.Anaxomics.com). TPMS facilitates the screening of drugs for their capacity to shift the profile of 
topological molecular maps from pathological to beneficial1. We used TPMS to identify known drugs likely to be 
beneficial in treatment of peripheral nerve lesions caused by trauma, tumors, or autoimmune reactions. The eco-
nomic cost of treating injured patients is considerable due to both direct and indirect expenses, as the injuries tend to 
cause functional inability in previously productive people2. Nerve root avulsion (RA) leads to the most severe degree 
of nerve injury because nerves are completely separated from the spinal cord and sensory ganglia, thus causing loss 
of motor, sensory, and autonomic functions in the affected extremities3. RA often leads to deafferentation pain that 
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may develop into central sensitization and severe neuropathic pain that is refractory to pharmacotherapy4. Detached 
nerves may be reimplanted but successful repair is time-dependent due to the existence of massive retrograde degen-
eration of motoneurons (MNs)5. Thus, effective therapeutic agents should target multiple mechanisms in order to 
maintain MN viability, promote regenerative capabilities, and minimize glial reactivity.
In order to discover such a multifunctional therapy, we built molecular maps using TPMS and quantitative 
and unbiased proteomic data obtained from a pre-clinical rat model of RA that leads to retrograde degeneration 
of MNs and from a rat model of distal axotomy (DA) and suture that leads to MN survival and nerve regenera-
tion6. We screened these maps for neuroprotective combinations of FDA-approved drugs, and we validated the 
selected combinations in the RA model. We found that the combination of acamprosate (ACA) plus ribavirin 
(RIB), which we called NeuroHeal, promotes neuroprotection, nerve regeneration, and functional recovery and, 
unlike existing drugs, is not pro-nociceptive. The mechanism of action of NeuroHeal involves sirtuin 1 (SIRT1), 
an actively pursued therapeutic target. NeuroHeal thus warrants further evaluation for early treatment after 
peripheral nerve and RA injuries.
Results
Identification of putative neuroprotective drug combinations. To identify potential neuroprotective 
drug combinations, we applied machine-learning tools as depicted in Fig. 1A. To generate our systems biology-based 
networks, the starting material was a manually curated list composed of proteins clustered in motives likely to be 
involved in either “neuroprotection” or “neurodegeneration” and obtained from a perusal of the literature in PubMed 
(Supplementary Tables 1 and 2). The initial list was expanded to generate network maps that included 3,296 proteins for 
regeneration and 3,836 proteins for degeneration with an overlap of 2,232 proteins. Snapshot of the maps are shown in 
Fig. 1B. The maps were converted into mathematical models incorporating all biological knowledge available including 
drug targets and clinical trials results1,7–9. Drug repositioning solutions were acquired by perturbing the models with 
stimulus (drugs) and approximating the best solution to the neuroprotection model. We incorporated our experimental 
proteomic data from the RA and DA models previously published6 and categorized as degeneration and neuroprotec-
tion conditions, respectively, for machine training to generate physiological responses facing any perturbation. These 
data resulted in a set of restrictions that all mathematical solutions should accomplish. In addition, the drugs screened 
were required to: i) have an outstanding safety profile, ii) not cause neuropathic pain, iii) have no known effects on 
CNS/PNS regeneration, and iv) be able to cross the brain-blood barrier. A total of 5,440 drugs that generated approx-
imately 15 million binary combinations were screened. The threshold for drug candidates is calculated based on the 
cross-validation of the approved indications for each drug. We obtained 33 combinations that accomplished predicted 
values for peripheral nerve regeneration of 23%, for neuropathic pain of 17% or lower and more than 20% of syner-
gism. Among those, several combinations contained at least one compound that had reported effects over regenerative 
properties. Hence, we further selected those combinations with standout safety profile and priority art. From the scored 
resulting binary combinations (Fig. 1C) we selected the top 3, having more than 75% of potential regenerative capabil-
ities and less than 2.5% relation with neuropathic pain formation, for further experimental validation: ACA plus RIB 
(Combination C1); ACA plus ephedrine (EPHE) (C2), and S-adenosylmethionine (SAM) plus EPHE (C3).
In vitro and in vivo validation of drug combinations. To validate the neuroprotective effect of the drug 
combinations and the synergy between their components we used an in vitro model of endoplasmic reticulum 
(ER) stress, since this is a hallmark of the RA neurodegenerative process10. We treated differentiated NSC-34 
MN-like cells with tunicamycin (TN, an ER stressor), vehicle, individual drugs, or one of the drug combinations 
(C1-C3) and assessed viability with the MTT assay. Drug combinations, but not single drugs with the exception 
of SAM, protected the cells against ER stress (Fig. 2A).
We next performed RA in animals that received treatment with vehicle, single drugs, or drug combinations using 
subcutaneous implanted programmable pumps for continuous intrathecal infusion during 20 days post-injury. We 
used Pre084, a selective agonist of receptor σ111, as a positive control of neuroprotection; Pre084 has no clinical value 
as it is pro-nociceptive12,13. Among all combinations, only C1(ACA + RIB) yielded a similar rate of MN survival as 
Pre084. Treatment with single C1 components ACA or RIB alone did not promote neuroprotection (Fig. 2B). Next, 
in order to determine the specificity of neuroprotection, we treated RA animals with a non-relevant combination 
composed of meflokine (MEF) and alitretionion (ALI), which we previously discovered using a similar systems 
biology approach for amyotrophic lateral sclerosis1. The drug combination reached its target after a continuously 
pumped infusion because there was upregulation of choline acetyl transferase (ChAT) expression within the MNs 
of treated RA animals (Fig. 2C) as previously demonstrated1. However, the combination was not neuroprotective 
(Fig. 2D), suggesting that the results obtained with TPMS were highly pathology-specific.
C1 and C3 treatments, in contrast to C2, reduced both microgliosis and astrogliosis after RA, as determined 
by immunohistochemical analysis of GFAP-positive astrocytes and Iba1-positive microglia (Fig 3A,B). Of drugs 
given individually only RIB slightly reduced astrogliosis (Fig. 3B). To examine the existence of a pro-regenerative 
profile within MNs, we analyzed the expression of GAP43, a protein associated with proliferation, in the motor 
axonal branches on the lateral-ventral side of the ipsilateral versus contralateral spinal cord sections. Most of the 
combinations analyzed and ACA alone, but not after Pre084 or RIB, increased GAP43 levels (Fig. 3B). We scored 
all drug combinations with regards to neuroprotection, reduction of inflammation, regeneration, and ER stress 
protection in vitro (Fig. 3C). C1(ACA + RIB) was the best in all readouts, and we named it NeuroHeal.
Determination of drug synergy in NeuroHeal. In order to determine the optimal dose combination we 
assayed ACA and RIB in different concentrations, changing by approximately 10-fold the amount of one drug with 
respect to the other. The fixed, 1X concentrations were 0.22 mM for ACA and 4 µM for RIB. We measured pro-
tection against cellular death caused by ER stress using the MTT assay. Neuroprotection was observed in a range 
of 0.1X to 1X for individual drugs, but not with higher doses (10X) (Fig. 4A, left). We next narrowed the range of 
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Figure 1. Experimental design. (A) The starting material was a manually curated list of key proteins clustered 
in motives that allowed construction of condition-specific networks for neurodegeneration after RA and for 
neuroprotection after DA. Using TPMS, network static maps were converted into topological maps associated 
with mathematical equations. The available data from unbiased proteomic analysis generated from RA and 
DA models (Casas et al., 2015) was used to build a set of restrictions collated into a truth table with which all 
models generated had to comply. Drug screening in silico was used to perturb the neurodegeneration-associated 
mathematical model and drug combinations that approximated the model to the neuroprotective state were 
identified. The algorithms used also allowed specification of key proteins involved in the mode of action (MoA) 
of each drug combination. Finally, we validated new combinations for its neuroprotective effect and putative 
MoA in vivo and in vitro. (B) Snapshots of the full protein networks associated with the neurodegenerative 
condition after RA (left, 3,836 nodes, average links per node 13.4) and with the neuroprotective condition after 
DA (right, 3,296 nodes, average links per node 13.9) visualized through the Cytoscape software platform62. Seed 
proteins for different motives are labelled by colour as indicated. Some seeds belong to more than one motive. 
(C) List of potential neuroprotective drug combinations identified using the in silico screen.
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Figure 2. Neuroprotection by drug combinations identified in silico. (A) Bar graph showing the percentage of 
cell survival ± SEM after treatment with different doses of TN, which causes ER stress, to establish the optimal 
concentration to be used in vitro (fixed at 1 µg/ml TN). Neurotoxicity was evaluated with an MTT assay on 
differentiated NSC-34 MN-like cells in the absence of treatment (control, ctrl) or vehicle (veh) or presence of 
a single drug (Pre084, ACA, Rib, SAM, or EPHE or drug combinations (C1-C3) analysed 24 h after adding 
treatments (n = 3–8, *p < 0.05 vs. vehicle, #p < 0.05 vs. 1 µg/ml TN). (B) Top, representative microphotographs 
of spinal cord ventral horns at L4-L5 from sham-operated control or the ipsilateral side of RA animals stained 
with fluorescent Nissl. Animals were intrathecally treated using programmable infusion pumps with either 
vehicle (artificial cerebrospinal fluid), PRE084 (positive control), single drugs, or combination of drugs: 
C1 = ACA (drug A) + RIB (drug B); C2 = EPHE + ACA; and C3 = SAM + EPHE. Scale bar = 100 µm. Bottom, 
bar graph of the average relative number of surviving motoneurons ± SEM on the ipsilateral side with respect 
to the contralateral side after 21 days post injury (dpi; n = 3 for Sham, PRE084, C3; n = 6 for injured; n = 4 for 
www.nature.com/scientificreports/
5SCIENtIfIC REPORTS |  (2018) 8:1879  | DOI:10.1038/s41598-018-19767-3
concentrations from 0 to 2X. ACA or RIB treatment alone had no significant neuroprotective effect. In contrast, 
C1(ACA + RIB) afforded neuroprotection from 0.1X until less than 1X (Fig. 4A). Statistical analysis performed as 
previously described14 revealed a supra-additive effect when the drugs were combined to form NeuroHeal. Thus, for 
in vivo testing, we chose two doses with the best outcomes: 0.22 mM ACA plus 0.4 µM RIB and 0.06 mM ACA plus 
1 µM RIB.
We administered these doses orally in RA injured animals because both drugs cross the blood-brain barrier 
in animals. The oral doses required to achieve effective of 0.22 mM ACA plus 0.4 µM RIB (dose 1) and 0.06 mM 
ACA plus 1 µM RIB (dose 2) in the CNS were estimated on the basis of previous pharmacokinetic studies of 
ACA and RIB in rats15–18. Both dose 1 and dose 2 caused a significant increase in MN survival as compared with 
vehicle-treated rats, although dose 2 was slightly more effective than dose 1 (Fig. 4B). We chose dose2 for further 
works and found that it reduced gliosis and promoted overexpression of GAP43 (Fig. 4C).
NeuroHeal promotes functional recovery. The regenerative potential of NeuroHeal was confirmed in a 
model of crush injury of the sciatic nerve. The compound muscle action potentials (CMAP) evoked in response to sci-
atic nerve stimulation were recorded in gastronecmius and plantar muscles to assess functional recovery of denervated 
muscles. NeuroHeal led to a significant increase in CMAP amplitude in both muscles during the follow-up (Fig. 5A). 
After 28 days, there was reinnervation of the plantar muscle in all of the treated rats but in only 40% of the untreated 
(Fig. 5B), suggesting that NeuroHeal accelerated nerve regeneration. Furthermore, NeuroHeal improved the recovery 
of motor function, evaluated with the sciatic functional index (Fig. 5C), and increased the number of reinnervated neu-
romuscular junctions, assessed with co-localization of NF-200 with α-bungarotoxin (Fig. 5D). The numbers of MNs in 
rats after nerve crush were not significantly different in vehicle and NeuroHeal treated animals (Fig. 5E).
The mechanism of action of NeuroHeal. TPMS analysis allowed the identification of putative proteins that 
mediate the synergistic mechanism of action (MoA) for NeuroHeal. The manually curated collection of molecular 
effectors (seeds) used in the model are listed in Fig. 6A. We used different platforms like STRING and IntAct as well 
as literature perusal to establish functional relationships among these proteins and the known targets of each drug 
composing NeuroHeal (Fig. 6B, Supplemental Figs 1 and 2). The known actions of ACA (DB00659) include the 
antagonism of the N-methyl-d-aspartate (NMDA) receptor and the metabotropic glutamate receptor 5 and the pos-
itive modulation of GABA receptor (A) (GABAR(A)). Hyperpolarization caused by Cl− entry due to GABAR(A)) 
stimulation is normally proceeded by a depolarization caused by L-type voltage-gated calcium channel activation19. 
The consequent entry of Ca2+ may trigger different pathways, importantly PI3K activation20. PI3K activation may 
lead to the pro-survival AKT and FOXO pathway activation21 and also to an increase in cytoskeletal dynamics22. In 
particular, it may favor vesicle trafficking such as the gephyrin-mediated transport of GABA receptors to the surface 
membrane helped by dynactin, Kif5, and Hap123,24 and nucleocytoplasmic shuttling mediated by Ran-binding pro-
teins (RANBP)25. PI3K activation may also promote the activation of Src-integrin complex which in turn confers 
anti-anoikis properties26,27. In particular, the Src-integrin complex together with ranbp9 may favour endocytosis, 
which is anti-amyloidogenic28. Other ranbp proteins may be also activated, such as ranbp9, which is linked to active 
endocytosis and prevents the generation of amyloid peptide.
RIB (DB00811) inhibits inosine-5′-monophosphate dehydrogenase 1, an enzyme that catalyzes the conversion 
of inosine 5′-phosphate to xanthosine 5′-phosphate and acts as immunodulator29. Since this reaction consumes 
NAD+, its inhibition may lead to NAD+ accumulation. Hence, SIRT1, a nicotinamide adenine dinucleotide 
(NAD+)-dependent histone deacetylase and sensor of the NAD+/NADH balance30 may activate NAD+/NADH 
metabolism in a process involving PDK1 and PKM31. This leads to deacetylation of p53, which inhibits apopto-
sis32 and deacetylation and reinforced activation of AKT and FOXO33,34, which regulates microtubule dynamics 
resulting in neuroprotection in a process that involves PLK1 and Dynactin35. Indeed, PLK1 has been shown to 
reduce cell death mediated by amyloid peptide36.
In order to validate this putative MoA, we evaluated the effect of NeuroHeal on expression of some of these 
proteins such as the subunit b1 of integrin (ITGb1), kinesin family member Kif5c6, SIRT1, and the dynactin 
subunit DCTN1 in MNs at the ipsilateral site after 21 days post injury (dpi) in the RA model. We found that 
NeuroHeal increased the cytosolic expression of ITGb1, Kif5c, DCTN1, and SIRT1 in the ipsilateral horn with 
respect to the contralateral (Fig. 6C). Of note, the normalized levels of cytosolic SIRT1 in NeuroHeal treated rats 
was mostly due to the reduction in injury-induced nuclear expression of the protein. DCTN1 analysis showed 
that the expression of the target protein was modulated exclusively on the ipsilateral side, suggesting that the MoA 
of NeuroHeal may be specific to the damage context.
Due to the importance of SIRT1 in many pathological conditions and in life span37, we investigated fur-
ther whether SIRT1 was activated by NeuroHeal. First, we sought to determine whether viral overexpression of 
SIRT1 resulted in neuroprotection after RA since, due to NAD+ depletion promoted by SIRT1, SIRT1 does not 
always promote neuroprotection30. We cloned the SIRT1 gene into a recombinant adeno-associated viral vector 
10 (AAVrh10), which we previously had reported as being highly specific to MNs when intrathecally delivered to 
the spinal cord38. SIRT1 overexpression was localized in MNs, mainly in the cytoplasm (Fig. 7A). Within avulsed 
other groups, ANOVA, post hoc Bonferroni *p < 0.05 vs. vehicle, #p < 0.05 vs. PRE084, $p < 0.05 vs. C1). (C) 
Microphotographs of ChAT immunohistochemistry in the ventral horn MNs from RA animals treated with 
vehicle (veh) or with a non-related drug combination of Mef and Ali at 14 dpi. Ali increases expression of ChAT. 
Bar graph of immunoreactivity intensity per area within MNs (Nissl-positive). (n = 3). (D) Representative 
microphotographs of MNs of the ipsilateral ventral horn stained by Nissl. Bar graph showing the average 
number of MNs ± SEM on the ipsilateral with respect to the contralateral side of spinal cord from animals 
treated with either vehicle or the combination of Mef and Ali at 21 dpi. (n = 3).
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Figure 3. All drug combinations reduce microgliosis and astrogliosis and promote neuronal regeneration. (A) 
Representative fluorescence microphotographs at low magnification of the ipsilateral ventral horns of the spinal 
cord from RA injured animals treated with vehicle (Veh), Pre084, or drug combinations (C). Top and middle 
panels, staining for astrocytes (GFAP) and (middle panel) microglia (Iba1), respectively, in grey matter (GM)—
delimited with dashed lines. Bottom panels, GAP43-positive neurites at the white matter (WM) of the ipsilateral 
ventral horns. Scale bar = 100 μm. (B) Bar graph of average immunoreactivity intensities in GM for GFAP and 
Iba1 and in WM for GAP43 (*p < 0.05 vs. Veh, #p < 0.05 vs. C1). (n = 4). (C) Table summarizing dichotomy 
scores for MN survival, gliosis, and pro-regenerative effects in vivo and neuroprotective effects in vitro (1 is 
beneficial effect and 0 indicated no effect).
www.nature.com/scientificreports/
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MNs, infection with AAVrh10-GFP did not change the nuclear ring-like pattern of SIRT1 expression induced by 
RA, but infection with AAVrh10-SIRT1 led to accumulation of SIRT1 predominantly in the cytoplasm of MNs, 
similar to NeuroHeal’s effect (Fig. 7A).
Second, we measured the deacetylase activity of SIRT1 by assessing the contents of histone-H3 acetylated at 
Lys9 (H3-K9) and of p53 acetylated at Lys373 (p53-K373) residues39,40. In RA animals treated with AAVrh10- 
SIRT1we observed: i) a decrease in both H3-K9 and p53-K373 acetylated forms, suggesting that SIRT1 overex-
pression caused an activity increase (Fig. 7B) and ii) a significant increase in MN survival (up to 52.90% ± 1.79) 
(Fig. 7C). Together these results suggest that overexpression and subsequent enhanced activation of SIRT1 is 
neuroprotective in severe peripheral nerve lesions.
Third, we evaluated the effect of NeuroHeal in combination with either a specific inhibitor of SIRT1, Ex-527, which 
promotes the persistence of acetylated forms, or spermidine, an inhibitor of acetylases that causes the persistence of 
deacetylated forms41. Rats were treated with NeuroHeal and either Ex-527 or spermidine using the continuous intrath-
ecal pump perfusion system for 20 days post RA injury. As readouts, we used nuclear SIRT1, H3-K9, and p53-K373 
in injured MNs at the ipsilateral ventral horn. Maximal expression of all markers was observed in untreated and 
vehicle-treated mice. Spermidine did not alter SIRT1 distribution but, as expected, reduced H3-K9 and p53-K373 levels 
(Fig. 8A). NeuroHeal reduced nuclear levels of SIRT1 and acetylated forms of H3 and p53 and this effect was reversed 
by Ex-527 but not spermidine (Fig. 8A). Accordingly, spermidine, either alone or in combination with NeuroHeal, 
increased the survival rate of MN whereas Ex-527 abolished the neuroprotective effect exerted by the drug (Fig. 8B).
Finally, we compared the regenerative and anti-inflammatory capacities of NeuroHeal with those of virally 
transduced SIRT1 and spermidine. Although all treatments were neuroprotective, only NeuroHeal promoted 
GAP43 expression and reduced microgliosis and astrogliosis (Fig. 8C,D). These results demonstrate that 
Figure 4. NeuroHeal has a supra-additive neuroprotective effect and is effective upon oral administration. 
(A) Left, Bar graph of NSC-34 cell survival upon ER stress measured by MTT assay at different dose ratios of 
ACA (A; 1X = 0.22 mM) to RIB (R; 1X B = 4 µM). Right, Effect of range of doses within 0–2X with NeuroHeal 
or with single drugs at 1X (p < 0.05 with respect to TN alone). (B) Representative microphotographs of 
MNs stained by Nissl at the ipsilateral ventral horns of RA animals treated orally with either vehicle or dose 
1 (0.22 mM ACA + 0.4 µM RIB) or dose 2 (0.06 mM ACA + 1 µM RIB), and bar graph of the percentage of 
surviving MN cells at the ipsilateral side with respect to the contralateral side. (n = 4). (C) Bar graph of average 
immunoreactivity intensity for GFAP, Iba1, and GAP43 in a fixed region of interest in the ipsilateral ventral 
horn in grey matter for GFAP and Iba1 staining or white matter for GAP43 (n = 4; *p < 0.05 vs. vehicle).
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deacetylation is important for the NeuroHeal-mediated neuroprotection after RA and that, synergistically acting 
through multiple targets, NeuroHeal performs better than single-target drugs.
Discussion
Network medicine has become increasingly important for identifying novel disease mechanisms and predicting 
drug effects. This network-based approach enables elucidation of the underlying molecular mechanisms, mainly 
in terms of disease modules, disease phenotypes, and disease-disease associations42–44. A number of studies have 
investigated the disease modules associated with specific disease phenotypes such as asthma, diabetes, and cancer, 
for which a single disease module would mainly be detected45,46. That there should be a shift in the paradigm of 
drug discovery from a focus on single targets to the systems has been argued47, particularly in neuropathology48.
We reasoned that proteomic profiles from suitable preclinical models of MN neurodegeneration would provide 
unbiased data for use as input to machine learning and mathematical modeling to search for novel drug combi-
nations. We took advantage of the existence of advanced molecular knowledge of the dissimilar reactions in MNs 
after either proximal or distal axotomy with opposite readouts (degeneration vs. survival, respectively). The ration-
ale was that mimicking the endogenous mechanism that MNs engage in after distal axotomy should be neuropro-
tective. Computational tools available allowed us to screen for known drugs that in silico perturb the RA model 
to convert it into a DA model. We validated that some of the synergic drug combinations discovered in silico were 
neuroprotective in cell culture models and in vivo. The combination we call NeuroHeal had anti-inflammatory 
properties and induced pre-regenerative profiles in MNs. Furthermore, we identified the molecular downstream 
pathway that is modulated by NeuroHeal: SIRT1 is an important node in the network. Moreover, we validated that 
activation of SIRT1 mediated the neuroprotective action of NeuroHeal in a rat model of RA. To our knowledge this 
is the first work to demonstrate discovery of repurposed drug combinations using a network-centric approach with 
learning machine computational tools that moves forward from theory to practice and validates both the efficacy 
and mechanism of action using preclinical in vivo models. Previous partial studies have paved the way49–51.
Figure 5. NeuroHeal accelerates nerve regeneration and improves muscle reinnervation and functional 
recovery after nerve crush injury. (A) Left panels, mean amplitudes of CMAP from ipsilateral gastrocnemius 
and plantar muscles after sciatic nerve crush of animals treated with vehicle (Veh) or NeuroHeal (C1; n = 5, 
ANOVA, post hoc Bonferroni*p < 0.05 vs. Veh). Right panels, representative recordings. (B) Histogram of the 
percentages of treated animals that presented electrophysiological evidence of reinnervation at the plantar 
muscle at different time-points. (C) Left, Plot of the sciatic functional index (SFI) obtained with walking 
track analysis of sciatic nerve in RA animals treated with either vehicle (Veh) or NeuroHeal (C1). Right, 
Representative footprints from ipsi- and contralateral paws at 35 days post injury (dpi). (D) Left, bar graph 
showing the percentage of reinnervated motor endplates at plantar muscle. Right, representative pictures of 
reinnervated neuromuscular junctions showing nerve fibers immunostained by NF200 (red) and end-plates 
labeled with bungarotoxin (green). (n = 4). (E) Microphotographs of spinal MNs stained with Nissl green at the 
ventral horn showing no signs of cell death due to nerve crush at 3 weeks post-injury.
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Combined actions of ACA and RIB in NeuroHeal resulted in neuroprotection probably by exerting 
anti-apoptosis and anti-anoikis actions that we previously had shown to be key elements to activate the endog-
enous mechanisms of neuroprotection in axotomized MNs6. In the same report and in others5, the importance 
of cytoskeletal rearrangements for neuroprotection was also revealed; these rearrangements also appear to be 
facilitated by the NeuroHeal MoA. It would be interesting to validate the role of these and the others described 
processes in NeuroHeal MoA, similarly to what we have done for SIRT1.
Figure 6. Molecular targets of NeuroHeal. (A) List of seed proteins predicted to be key synergic targets in 
the action of NeuroHeal. (B) Representation of putative NeuroHeal MoA from initial ACA and RIB targets to 
downstream possible effects to yield the synergic effects (pink) through its targets (orange). Representation 
is based on analysis using STRING and IntAct platforms and manual scrutiny of relevant literature. (C) Left, 
microphotographs of ipsilateral (I) and contralateral (C) ventral horns immunostained to reveal Itgb1, Kif5c, 
and SIRT1 in MNs (red) counterstained with green fluorescent Nissl (merged pictures) in animals treated 
with vehicle (Veh) or NeuroHeal (C1). Scale bar = 50 μm. Right and Bottom, bar graphs of the average ratios of 
immunofluorescence intensity (IF) between ipsi- and contralateral sides within an equivalent pre-determined 
region of interest (ROI) localized in the lateral grey matter for all conditions except for DCTN1, which was 
measured in the white matter (n = 4 animals, 5 MN/section, 3 sections, *p < 0.05). The bottom right histogram 
of DCTN1 analysis shows the quantification of total integrated intensity on each side to document that 
NeuroHeal only changes expression on the injured site (n = 4 animals, 5 MN/section, 3 sections, *p < 0.05).
www.nature.com/scientificreports/
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NeuroHeal activated SIRT1 in damaged MNs after axonal disconnection. This is an interesting discovery 
because SIRT1 activators have long been sought due to the beneficial effects likely for several diseases52–54. 
Although SIRT1 is important for neurodegeneration55, it does not always lead to neuroprotection because it 
exhausts NAD+ resources30. The main advantage of NeuroHeal as compared to other recently discovered 
small-molecule sirtuin-activating compounds (e.g., STAC)37 is that its components have been proven to be safe 
for humans and cross the blood-brain barrier. Of note, NeuroHeal has effects beyond SIRT1 activation since it 
also promotes the expression of the pro-regenerative marker GAP43, while overexpression of SIRT1 does not. 
Finally, although we found that spermidine also affords neuroprotection of MNs after RA, its use in the clinic 
has been avoided as it is nociceptive56. Our work indicates that the role of epigenetic switches in neuroprotection 
deserves further investigation.
Unexpectedly, we found that NeuroHeal promoted nerve regeneration and functional recovery after 
nerve crush. This finding suggested that the proteomic data used from DA models may contain intrinsically 
pro-regenerative factors. It would be worth testing this hypothesis in more severe models to study CNS axon 
regeneration.
The properties of NeuroHeal make it a first-in-class therapeutic agent for nerve root disconnection or 
entrapments. The translation of NeuroHeal to the clinic will be facilitated because it is composed of already 
Figure 7. SIRT1 overexpression promotes MN survival after RA. (A) Top, representative microphotographs 
of SIRT1 immunolabelling (red) in infected MNs in control animals (upper) and RA injured animals (lower) 
treated with either AAVrh10-GFP or AAVrh10-SIRT1 and counterstained with green fluorescent Nissl. Scale 
bar = 100 µm (top); 25 µm (bottom). Bottom, histogram of cytosolic versus nuclear SIRT1 localization in the 
RA-injured MNs 21dpi after damage. (B) Histogram of the percentage of avulsed MNs with high nuclear 
immunofluorescence intensity for each acetylated form of either H3 (H3-K9) or p53 (p53-K373) at the 
ipsilateral side of RA animals infected with either vector (n = 4, *p < 0.05 vs. AAV-GFP). (C) Representative 
microphotographs of Nissl-labelled MNs (green) at the ipsilateral ventral horns of RA animals treated with 
either AAVrh10-GFP or AAVrh10-SIRT1and histogram of MN survival ± SEM expressed as % of MN on the 
contralateral side (contra) (n = 4, *p < 0.05 vs. AAVrh10-GFP).
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FDA-approved drugs. Knowledge about formulation is also advanced because we assessed the effect of different 
stoichiometry combinations of single drugs to achieve neuroprotective synergism.
We conclude that our network-centric discovery approach encompassing proteomic data relevant to disease 
and artificial intelligence is a powerful and promising methodology for the design of effective treatments based 
on drug repurposing. Repurposing speeds up the clinical translation of treatments for complex pathological con-
ditions. Patent protection of NeuroHeal is currently in progress and funding is being raised in order to test the 
drug in a clinical trial.
Figure 8. SIRT1 mediates the neuroprotective effect of NeuroHeal. (A) Diagram of the mechanisms of action of 
spermidine and Ex-527 and bar graph of the percentage of avulsed MNs with high nuclear immunofluorescence 
intensity for each marker on the ipsilateral side of RA animals treated with different drugs (n = 6 for untreated; 
n = 3 for Veh DMSO; n = 4 other groups, ANOVA, post hoc Bonferroni*p < 0.05 vs, #p < 0.05 vs. C1, $p < 0.05 
vs. C1 + Sperm, &p < 0.05 vs. Sperm). (B) Representative microphotographs of MNs on the ipsilateral sides and 
associated histogram of the average percentage of MN survival ± SEM in animals intrathecally treated with 
spermidine (Sperm) or Ex-527 with or without NeuroHeal (C1) (n = 4, ANOVA, post hoc Bonferroni *p < 0.05 
vs. untreated, #p < 0.05 vs. veh, $p < 0.05 vs. C1 + Ex-527, *p < 0.05). Scale bar = 100 μm. (C) Microphotographs 
of GAP43 immunostaining at the ventral horns of the ipsilateral sides from animals treated with either 
AAVrh10-GFP, AAVrh10-SIRT1 or C1. Scale bar = 100 µm. Bar graph of the average immunoreactivity in 
a fixed region of interest of the white matter (n = 3–4, *p < 0.05 vs. AAVrh10-GFP). (D) Representative 
microphotographs of astrocyte (GFAP) or microglia (Iba1) staining at the ventral horns of the ipsilateral sides 
of RA animals treated with either NeuroHeal (C1) or spermidine (Sperm). Scale bar = 100 μm. Associated bar 
graphs of the average immunoreactivity in a fixed region of interest of the grey matter (*p < 0.05 vs. C1).
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Materials and Methods
TPMS technology. TPMS is a top-down systems biology approach with applications in drug repositioning 57,19. 
It is based on artificial intelligence and pattern recognition models that integrate all available biological, phar-
macological, and medical knowledge to create mathematical models that simulate in silico the behaviour of 
human physiology. The process encompasses five steps: (i) A manually curated collection of molecular effectors 
(seeds) that characterize degeneration after RA and neuroprotection after DA, respectively, were created; (ii) 
condition-specific molecular maps were prepared from these seeds that incorporate all the available functional 
relationships; (iii) each static map was converted into mathematical models (topological maps) capable of repro-
ducing existing knowledge and predicting new data; (iv) our own proteomic data from RA and DA models were 
used to feed machine learning and generate a set of restrictions that make up the truth table, and (v) mathematical 
models were solved to obtain multicomponent drug neuroprotective candidates for RA and a minimal descrip-
tion of its synergic MoA. For details see Supplementary materials.
Subjects and surgical procedures. Sprague–Dawley female rats aged 12 weeks were kept under standard 
conditions of light and temperature and given food and water ad libitum. We performed surgical procedures 
under anaesthesia with a cocktail of ketamine/xylazine (0.1 mL/100 g weight) intraperitoneally (i.p.) as reported 
previously5. To perform extravertebral avulsion of the L4-L5 roots (the RA model) we made a midline skin inci-
sion and applied a moderate traction on the selected roots away from the intervertebral foramina, exposing the 
mixed spinal nerves that contained the motor and sensory roots and dorsal root ganglia. To carry out the sciatic 
nerve crush injury, we exposed the right sciatic nerve and crushed it in three different orientations using fine 
forceps (Dumont no. 5) for 30 seconds. The wound was sutured by planes and disinfected with povidone iodine, 
and the animals were allowed to recover in a warm environment. For intrathecal delivery of vehicle or drugs to 
the avulsed animals we used iPrecio programmable pumps (Data Science International, Italy), placed subcuta-
neously on the lumbar left side of the animal. The catheter connected to the pump was inserted into the magna 
cistern in the brain stem and fixed with surgical adhesive58. The pumps were programmed to release 30 µL from 
18 to 20 hours after injury to reach the desired concentration in the CSF after a 1:5 dilution. Then, a continuous 
flow of 1 µL/h was released during 20 days from the day following RA until sacrifice to maintain the desired con-
centration in the CSF. All procedures involving animals were approved by the ethics committee (Comissió d’Ètica 
i experimentació animal i Humana) of the Universitat Autònoma de Barcelona and Comité de Seguretat i Salut de 
la Generalitat de Catalunya, and followed the European Council Directive 2010/63/EU.
Electrophysiological and functional examination. See supplementary methods.
Drugs. Pre084 (Tocris, Ellisville, MO, USA), mefloquine (Mef), alitetrinoin (Ali), S-adenosylmethionine 
(SAM), ephedrine (EPHE), acamprosate calcium (ACA), ribavirin (RIB; Norman), and Ex-527 (Sigma-Aldrich, 
Saint Louis, MO, USA) were diluted in artificial cerebrospinal fluid (aCSF: 124 mM NaCl, 3 mM KCl, 26 mM 
NaHCO3, 2 mM CaCl2∙2H2O, 1 mM MgSO4∙7H2O, 1.25 mM KH2PO4, and 10 mM D-glucose) used as a vehicle 
alone or with 0.01% DMSO in the case of comparative studies with Ex-527. The concentrations prepared in the 
pumps were 5 × the desired final concentration in animal CSF: 0.015 mM for MEF, 0.15 mM for ALI, 5 mM for 
ACA, 20 µM for RIB, 36.5 µM for EPHE, 187 µM for SAM, 50 µM for Pre084, and 7 mM for Ex-527. We added 
spermidine (Sigma-Aldrich) to the drinking water; it was freshly added at 30 mM concentration every 2–3 days 
for 21 days as described elsewhere41. For oral administration, ACA (Merck, Darmstadt, Germany) and RIB 
(Normon, Madrid, Spain) were dissolved in water at a final concentration of 2.2 mM and 1 mM, respectively for 
dose 2 (0.25 × group).
Construction, purification, and infection with recombinant adeno-associated vectors. The SIRT1 
cDNA was cloned into NheI and XhoI sites between the ITRs of AAV2, under the regulation of CMV promoter 
and the woodchuck hepatitis virus responsive element (WPRE)59. AAV2/rh10 vector was generated as previously 
described60 by triple transfection of HEK 293-AAV cells (Stratagene, San Diego, CA, USA) with branched polyeth-
ylenimine (PEI; Sigma-Aldrich) with the plasmid containing the ITRs of AAV2, the AAV helper plasmid containing 
Rep2 and Cap for rh10 (kindly provided by JM Wilson, University of Pennsylvania, Philadelphia, PA, USA) and the 
pXX6 plasmid containing helper adenoviral genes61. Recombinant vectors were clarified after benzonase treatment 
(50 U/mL, Novagen) and polyethylene glycol (PEG 8000, Sigma-Aldrich) precipitation. Vectors were purified by 
iodixanol gradient by the Vector Production Unit at UAB (http://sct.uab.cat/upv), following standard operating 
procedures61. Viral genomes per ml (vg/ml) were quantified by picogreen (Invitrogen, Carlsbad, CA, USA).
Intrathecal administration of 4 × 10−10 viral genomes was performed at the lumbar region of 
isoflurane-anaesthetized animals using a 33-gauge needle and a Hamilton syringe. After lateral spine exposure by 
paravertebral muscle dissection, 10 µl of viral vectors were slowly injected into the CSF between vertebrae L3 and 
L4. Appropriate access to the intrathecal space was confirmed by animal tail flick. The needle was held in place at 
the injection site for one additional minute, after which muscle and skin were sutured.
In vitro model. We used the NSC-34 motoneuron-like cell line cultured in Dulbecco’s modified Eagle’s 
medium high-glucose (DMEM, Biochrom, Berlin) supplemented with 10% fetal bovine serum and 1X penicil-
lin/streptomycin solution (Sigma-Aldrich), on collagen-coated plates (Thermo-Fisher, Waltham, Massachusetts, 
USA) in a humidified incubator at 37 °C under 5% CO2. For ER stress we used added tunicamycin (0, 0.1, 1, or 
10 µg/ml; Sigma-Aldrich) and MTT assay was performed as detailed in supplemenatry methods.
Immunohistochemistry and image analysis. After deep anaesthesia with pentobarbital, we transcardi-
ally perfused the animals with a saline solution containing 10 U/ml heparin, followed by 4% paraformaldehyde 
in a 0.1 M phosphate buffer, pH 7.2 for tissue fixation at 21 dpi (n = 4 for each condition), and removed the L4 
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and L5 segments (5-mm total length) of the spinal cord, which were post-fixed in the same fixative for an extra 
4 hours and cryopreserved in 30% sucrose overnight. Serial transverse sections (20-µm thick) were obtained on 
gelatinized slides using a cryotome (Leica, Heidelberg, Germany) and preserved them at −20 °C until use. For 
immunohistochemistry procedures see supplemental material. Sections to be compared were processed together 
on the same slide and on the same day. Images of the spinal cord samples from different treatments and controls 
were taken under the same exposure time, sensibility, and resolution for each marker analysed with the aid of a 
digital camera (Olympus DP50) attached to the microscope (Olympus BX51). We analysed signal intensity with 
the ImageJ software (National Institutes of Health; available at http://rsb.info.nih.gov/ij/). For GFAP and Iba1, 
microphotographs were taken at 40 × , and then we transformed them to grey scale and analysed immunoreac-
tivity by measuring the integrated density of a region of interest (ROI) after defining a threshold for background 
correction5. The ROIs were selected on the grey matter at the ventral horn and had an area of 0.12 mm2 for GFAP 
and Iba1 and the same ROI size but in the white matter for GAP43 and DCTN-1. Measurements were performed 
from 8 spinal cord sections (separated 220 µm between pairs) of each animal.
Confocal microphotographs of nuclei of MNs were taken in identical conditions of exposure (Zeiss LSM 700; 
Zeiss, Jena, Germany). For SIRT1 and deacetylase activity substrate (p53K373 and H3k9) analysis, single-cell 
densitometry was performed by pre-defining the threshold for each section for background correction and meas-
uring the total area of the encircled MN nucleus. Then the ratio of integrated density/area was used as an index to 
classify at least 15–20 MNs per section.
Motor neuron counting. See supplementary methods
Neuromuscular junction reinnervation analysis. We cut the plantar interossei muscles into serial 
transverse sections (40 µm thick) using a cryotome and preserved them at −20 °C until use. The slides were 
incubated with chicken anti-Neuro Filament 200 (NF-200; 1:1000, Millipore) as described above. After several 
washes Cy3-conjugated secondary antibody was added. Finally, we incubated slices with α-bungarotoxin label-
ling solution (Life Technologies) following the manufacturer’s protocol to reveal motor endplate machinery. 
Sequential microphotographs were taken covering all the plantar muscle at 20 × . Only motor end plates with 
NF-200 co-labelling were counted as reinnervated.
Statistical analysis. All values are presented as means ± standard errors of the means (SEM). For statis-
tical analysis, we analyzed data with GraphPad Prism 5 software (San Diego, CA, USA) using unpaired t-tests 
or one-way analysis of variances (ANOVA) followed by Bonferroni’s multiple comparison tests. We considered 
differences significant at p < 0.05.
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